ACE2 and neoplasm: ACE2 deficiency was shown to increase the risk of hepatocarcinogenesis and the resistance to anti-PD-L1 immunotherapy, while promoting a permissive tumor microenvironment associated with M2-like macrophages, angiogenesis, and immunosuppressive myeloid cells [114].